Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05400967
Overview
FAP is a fibroblast activation protein and overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-EB-FAPI--a new 177Lu therapeutic drug modified by Evans Blue (EB) for the first time in the world.
Phase
Early Phase 1
Contacts
Zhaohui Zhu
13611093752@163.com
86-13611093752
Rongxi Wang
pumch_jacobwong@163.com
ClinicalTrials.gov
NCT05400967Help us improve your experience